Research Tree Research Tree Logo

  • Try our Investor Tool
  • Login
  • Sign Up

Research Tree Logo

  • Login
  • Sign Up
  • Features
  • Pricing
  • Reg.News
  • Contact
  • Try our Investor Tool
  • Login
  • Sign Up
  • Providers
  • Companies
⨯
LIVE

Event in Progress:

Join Here ×
  • Providers
  • Companies
⨯
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest
  • Contact
Companies >
UK >
Pharmaceuticals >
C4X Discovery Holdings PLC >
Research >
Rational drug design

working
  • 23 Sep 2015

Rational drug design


C4X Discovery Holdings PLC (C4XD:LON) | 26.0 0 0.0% | Mkt Cap: 59.6m


  • Edison
Pharmaceuticals image



 
Pharmaceuticals image



C4XD is developing its own pipeline of drug discovery programmes. The addiction programme’s lead candidate, a selective OX1 antagonist, is in formal preclinical studies. Two further programmes are expected to show preclinical proof of concept by the year-end. The proprietary technology platform enables improved and accelerated drug discovery based on conformational design of solution structures. Collaborations with pharma and research companies on novel drug programmes provide both platform validation and steady, albeit modest, revenues (£0.6m in 2014).


Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

Rational drug design


C4X Discovery Holdings PLC (C4XD:LON) | 26.0 0 0.0% | Mkt Cap: 59.6m


  • Published: 23 Sep 2015
  • Author:
  • Pages:
  • Edison


C4XD is developing its own pipeline of drug discovery programmes. The addiction programme’s lead candidate, a selective OX1 antagonist, is in formal preclinical studies. Two further programmes are expected to show preclinical proof of concept by the year-end. The proprietary technology platform enables improved and accelerated drug discovery based on conformational design of solution structures. Collaborations with pharma and research companies on novel drug programmes provide both platform validation and steady, albeit modest, revenues (£0.6m in 2014).



More Content

More Content

C4X Discovery Holdings PLC on expanding its portfolio

Companies: C4X Discovery Holdings PLC

Proactive

C4X Discovery Technology Overview For Investors

Companies: C4X Discovery Holdings PLC

Five Minute Pitch TV

C4X Discovery Holdings highlight their good position for advancement and expansion in current year

Companies: C4X Discovery Holdings PLC

Proactive

C4X Discovery 'progressing well' with development of its programmes and partner discussions

Companies: C4X Discovery Holdings PLC

Proactive

SP Angel Healthcare Conditions- 12-04-2021

Companies: Novacyt SAS (ALNOV:PAR)C4X Discovery Holdings PLC (C4XD:LON)

SP Angel

Useful Links

  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub

Account

  • Login
  • Free Trial - Join Now
  • Contact
Follow us on Linkedin Follow us on Twitter

Share:

Copyright © 2022 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Blogs
    • Academy
    • Insights
    • News
    • Research Tree
    • The Naked Fund Manager
  • Ideas & Picks
    • Ideas Hub
    • Stock Pick League
    • Themes & Screens Hub
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Leisure, Tourism & Travel
      • Media
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Trusts, ETFs & Funds
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Align Research
      • BNP Paribas Exane - Sponsored Research
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Edison
      • Equity Development
      • eResearch
      • Fidante Partners
      • Five Minute Pitch TV
      • goetzpartners securities Limited
      • Hardman & Co
      • Inbound Capital
      • Independent Investment Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Magnitogorsk Iron and steel works
      • Mello Events
      • piworld.co.uk
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • RaaS - Research as a Service
      • Radnor Capital Partners
      • Research Tree
      • SEAL Advisors Ltd
      • ShareSoc
      • Trinity Delta
      • Yellowstone Advisory
    • High Net Worth Offering
      • Fox-Davies Capital
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cenkos Securities
      • Couloir Capital
      • Dowgate Capital
      • finnCap
      • First Berlin
      • First Sentinel
      • Hannam & Partners
      • Hybridan
      • Liberum
      • Longspur Research
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • The Life Sciences Division
      • VSA Capital
      • WHIreland
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane
      • BNP Paribas Exane - Sponsored Research
      • BRR Media
      • Bryan, Garnier & Co
      • Calderwood Capital
      • Calvine Partners
      • Canaccord Genuity
      • Capital Access Group
      • Cenkos Securities
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Dowgate Capital
      • Edison
      • Equity Development
      • eResearch
      • Fidante Partners
      • finnCap
      • First Berlin
      • First Sentinel
      • Five Minute Pitch TV
      • goetzpartners securities Limited
      • Hannam & Partners
      • Hardman & Co
      • Hybridan
      • Inbound Capital
      • Independent Investment Research
      • InterAxS Global
      • Kepler | Absolute Hedge
      • Kepler | Trust Intelligence
      • Liberum
      • London Stock Exchange
      • Longspur Research
      • Magnitogorsk Iron and steel works
      • Mello Events
      • Northland Capital Partners
      • Numis
      • Panmure Gordon
      • Peel Hunt
      • piworld.co.uk
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • RaaS - Research as a Service
      • Radnor Capital Partners
      • Research Tree
      • SEAL Advisors Ltd
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • SI Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • The Life Sciences Division
      • Trinity Delta
      • VSA Capital
      • WHIreland
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Video/Audio Interviews
      • BRR Media
      • Capital Access Group
      • Couloir Capital
      • Edison
      • Equity Development
      • Five Minute Pitch TV
      • piworld.co.uk
      • Proactive
      • QuotedData
      • RaaS - Research as a Service
      • Research Tree
      • Yellowstone Advisory
    • Event Providers
      • Capital Access Group
      • Cenkos Securities
      • Edison
      • Equity Development
      • Hardman & Co
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Mello Events
      • piworld.co.uk
      • QuotedData
      • Research Tree
      • ShareSoc
      • Shore Capital
      • VSA Capital
      • Yellowstone Advisory
  • Contact
  • Sign Up
  • Sign In